^
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
tisotumab vedotin-tftv Sensitive: A1 - Approval
|
tisotumab vedotin-tftv Sensitive: A1 - Approval
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
pembrolizumab + bevacizumab Sensitive: A1 - Approval
|
pembrolizumab + bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
paclitaxel + topotecan Sensitive: A2 - Guideline
|
paclitaxel + topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
pemetrexed Sensitive: A2 - Guideline
|
pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
mitomycin Sensitive: A2 - Guideline
|
mitomycin Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
topotecan Sensitive: A2 - Guideline
|
topotecan Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Cervical Cancer
|
NTRK3 fusion
|
Cervical Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cervical Cancer
|
NTRK2 fusion
|
Cervical Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Cervical Cancer
|
NTRK1 fusion
|
Cervical Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Cervical Cancer
|
NTRK3 fusion
|
Cervical Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cervical Cancer
|
NTRK2 fusion
|
Cervical Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Cervical Cancer
|
NTRK1 fusion
|
Cervical Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
TMB-H
|
Cervical Cancer
|
TMB-H
|
Cervical Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Cervical Cancer
|
MSI-H/dMMR
|
Cervical Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
cisplatin + topotecan Sensitive: A2 - Guideline
|
cisplatin + topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
CPB Sensitive: A2 - Guideline
|
CPB Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
VC Sensitive: A2 - Guideline
|
VC Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
CP Sensitive: A2 - Guideline
|
CP Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
TPB Sensitive: A2 - Guideline
|
TPB Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
cisplatin + etoposide oral Sensitive: A2 - Guideline
|
cisplatin + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
AGEN2034 + UGN-301 Sensitive: B - Late Trials
|
AGEN2034 + UGN-301 Sensitive: B - Late Trials
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
AGEN2034 Sensitive: B - Late Trials
|
AGEN2034 Sensitive: B - Late Trials
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
pembrolizumab + bevacizumab Sensitive: B - Late Trials
|
pembrolizumab + bevacizumab Sensitive: B - Late Trials
|
No biomarker
|
Cervical Cancer
|
No biomarker
|
Cervical Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
cemiplimab Sensitive: B - Late Trials
|
cemiplimab Sensitive: B - Late Trials
|
MSI-H/dMMR
|
Cervical Cancer
|
MSI-H/dMMR
|
Cervical Cancer
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Cervical Cancer
|
HER-2 overexpression
|
Cervical Cancer
|
trastuzumab Resistant: C1 - Off-label
|
trastuzumab Resistant: C1 - Off-label
|
HER-2 mutation
|
Cervical Cancer
|
HER-2 mutation
|
Cervical Cancer
|
neratinib Sensitive: C2 – Inclusion Criteria
|
neratinib Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
AB122 Sensitive: C2 – Inclusion Criteria
|
AB122 Sensitive: C2 – Inclusion Criteria
|
DDR
|
Cervical Cancer
|
DDR
|
Cervical Cancer
|
BAY 1895344 Sensitive: C2 – Inclusion Criteria
|
BAY 1895344 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
serplulimab Sensitive: C2 – Inclusion Criteria
|
serplulimab Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
AGEN2034 Sensitive: C2 – Inclusion Criteria
|
AGEN2034 Sensitive: C2 – Inclusion Criteria
|
PRDX2 overexpression
|
Cervical Cancer
|
PRDX2 overexpression
|
Cervical Cancer
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
PRDX1 overexpression
|
Cervical Cancer
|
PRDX1 overexpression
|
Cervical Cancer
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
AJUBA overexpression
|
Cervical Cancer
|
AJUBA overexpression
|
Cervical Cancer
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
IFNG gene signature overexpression
|
Cervical Cancer
|
IFNG gene signature overexpression
|
Cervical Cancer
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
FGFR3-TACC3 F17T8
|
Cervical Cancer
|
FGFR3-TACC3 F17T8
|
Cervical Cancer
|
ABSK091 Sensitive: C3 – Early Trials
|
ABSK091 Sensitive: C3 – Early Trials
|
CXCL8 elevation
|
Cervical Cancer
|
CXCL8 elevation
|
Cervical Cancer
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
TNFA elevation
|
Cervical Cancer
|
TNFA elevation
|
Cervical Cancer
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
IL6 elevation
|
Cervical Cancer
|
IL6 elevation
|
Cervical Cancer
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
TXN overexpression
|
Cervical Cancer
|
TXN overexpression
|
Cervical Cancer
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials
|
pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials
|
PD-L1 negative
|
Cervical Cancer
|
PD-L1 negative
|
Cervical Cancer
|
AGEN2034 Sensitive: C3 – Early Trials
|
AGEN2034 Sensitive: C3 – Early Trials
|
STK11 mutation
|
Cervical Cancer
|
STK11 mutation
|
Cervical Cancer
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
KMT2D mutation
|
Cervical Cancer
|
KMT2D mutation
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Cervical Cancer
|
PIK3CA mutation
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Cervical Cancer
|
PD-L1 overexpression
|
Cervical Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
KDR expression
|
Cervical Cancer
|
KDR expression
|
Cervical Cancer
|
recombinant human endostatin Sensitive: C3 – Early Trials
|
recombinant human endostatin Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Cervical Cancer
|
MSI-H/dMMR
|
Cervical Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Cervical Cancer
|
PD-L1 expression
|
Cervical Cancer
|
AGEN2034 + UGN-301 Sensitive: C3 – Early Trials
|
AGEN2034 + UGN-301 Sensitive: C3 – Early Trials
|
PD-L1 expression + JAK2 mutation
|
Cervical Cancer
|
PD-L1 expression + JAK2 mutation
|
Cervical Cancer
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
PD-L1 expression + STK11 mutation + JAK2 mutation
|
Cervical Cancer
|
PD-L1 expression + STK11 mutation + JAK2 mutation
|
Cervical Cancer
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
PD-L1 expression + STK11 mutation
|
Cervical Cancer
|
PD-L1 expression + STK11 mutation
|
Cervical Cancer
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
PD-L1 expression + KMT2D mutation
|
Cervical Cancer
|
PD-L1 expression + KMT2D mutation
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
PD-L1 expression + PIK3CA mutation
|
Cervical Cancer
|
PD-L1 expression + PIK3CA mutation
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Cervical Cancer
|
PIK3CA mutation
|
Cervical Cancer
|
alpelisib Sensitive: C3 – Early Trials
|
alpelisib Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Cervical Cancer
|
ARID1A mutation
|
Cervical Cancer
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
|
BRCA2 exon 11 deletion
|
Cervical Cancer
|
BRCA2 exon 11 deletion
|
Cervical Cancer
|
ABSK091 Sensitive: C4 – Case Studies
|
ABSK091 Sensitive: C4 – Case Studies
|
BRCA1 mutation + TP53 R248Q
|
Cervical Cancer
|
BRCA1 mutation + TP53 R248Q
|
Cervical Cancer
|
bevacizumab + olaparib Sensitive: C4 – Case Studies
|
bevacizumab + olaparib Sensitive: C4 – Case Studies
|
BRCA1 positive
|
Cervical Cancer
|
BRCA1 positive
|
Cervical Cancer
|
bevacizumab + olaparib Sensitive: C4 – Case Studies
|
bevacizumab + olaparib Sensitive: C4 – Case Studies
|
PD-L1 amplification
|
Cervical Cancer
|
PD-L1 amplification
|
Cervical Cancer
|
nivolumab Resistant: C4 – Case Studies
|
nivolumab Resistant: C4 – Case Studies
|
PIK3CA E542Q + TMB-H + MSI-H/dMMR
|
Cervical Cancer
|
PIK3CA E542Q + TMB-H + MSI-H/dMMR
|
Cervical Cancer
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
MAPK4 deletion
|
Cervical Cancer
|
MAPK4 deletion
|
Cervical Cancer
|
PARP inhibitor Sensitive: D – Preclinical
|
PARP inhibitor Sensitive: D – Preclinical
|
RAD51 underexpression
|
Cervical Cancer
|
RAD51 underexpression
|
Cervical Cancer
|
olaparib Sensitive: D – Preclinical
|
olaparib Sensitive: D – Preclinical
|
HUWE1 mutation
|
Cervical Cancer
|
HUWE1 mutation
|
Cervical Cancer
|
GS-626510 Sensitive: D – Preclinical
|
GS-626510 Sensitive: D – Preclinical
|
MYC overexpression
|
Cervical Cancer
|
MYC overexpression
|
Cervical Cancer
|
GS-626510 Sensitive: D – Preclinical
|
GS-626510 Sensitive: D – Preclinical
|
ROR1 expression
|
Cervical Cancer
|
ROR1 expression
|
Cervical Cancer
|
sirolimus Sensitive: D – Preclinical
|
sirolimus Sensitive: D – Preclinical
|
